Anti-mullerian hormone is higher in seizure-free women with epilepsy compared to those with ongoing seizures

被引:7
|
作者
Harden, Cynthia L. [1 ]
Pennell, Page B. [2 ]
French, Jacqueline A. [3 ]
Davis, Anne [4 ]
Lau, Connie [5 ]
Llewellyn, Nichelle [2 ]
Kaufman, Benjamin [3 ]
Bagiella, Emilia [1 ]
Kirshenbaum, Ariel [2 ]
机构
[1] Icahn Sch Med Mt Sinai, 1428 Madison Ave, New York, NY 11029 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] NYU, Sch Med, 462 1st Ave, New York, NY 10016 USA
[4] Columbia Univ, Med Ctr, 630 W 168th St, New York, NY 10032 USA
[5] Northwell Hlth, 611 Northern Blvd, Great Neck, NY 11021 USA
基金
美国国家卫生研究院;
关键词
Seizures; Anti-mullerian hormone; AMH; Epilepsy; Ovarian reserve; MEN;
D O I
10.1016/j.eplepsyres.2016.08.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine if anti-mullerian hormone (AMH), a neuroactive peptide hormone and a measure of ovarian reserve, is different between women with epilepsy (WWE) and healthy controls (HC) seeking pregnancy and to evaluate epilepsy-related factors associated with AMH concentrations. Methods: Subjects were participants in Women with Epilepsy: Pregnancy Outcomes and Deliveries (WEPOD), a multi-center prospective, observational cohort study evaluating fecundity in WWE compared to HC, ages 18-40 years. WWE were divided into a Sz+ group or a Sz- group, dependent on whether they had seizures within the 9 months prior to enrollment. Serum was collected, and AMH concentrations were measured as an exploratory analysis. Linear and logistic regression models were used to assess associations and control for covariates. Results: Serum AMH concentrations were measured in 72 out of 90 enrolled WWE and 97 out of 109 HC; the remaining subjects became pregnant before serum was obtained. Thirty WWE were in the Sz+ group and 40 in the Sz- group (retrospective seizure information was missing for two). All AMH concentrations were within the range, however, the normal inverse correlation between age and AMH was present in the HC and in the Sz- groups, but was lacking in the Sz+ group. Mean AMH concentration was higher in the Sz- group (3982 pg/ml (SD +/-2452)) compared to the Sz+ group of WWE (2776 pg/ml (SD +/-2308)) and HCs (3241 (SD perpendicular to 2647)). All values were within the expected range for age. In WWE, by linear regression, after controlling for age and BMI, seizure occurrence remained associated with AMH (p = 0.025). In the prospective phase of the study, AMH concentrations were also associated with seizure occurrence during the menstrual cycle in which the serum sample was obtained (p = 0.012). Antiepileptic drugs and other epilepsy factors were not associated with AMH concentrations. When analyzing the Sz- WWE group and the HC group by linear regression with AMH as the dependent variable, after controlling for age and BMI, the association with AMH was also present (p = 0.017). AMH concentrations of the Sz+ group and HCs did not differ. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [21] Anti-Mullerian hormone levels and fecundability in women with a natural conception
    Hvidman, Helene W.
    Bang, Anne Kirstine
    Priskorn, Laerke
    Scheike, Thomas
    Petersen, Kathrine Birch
    Nordkap, Loa
    Loft, Anne
    Pinborg, Anja
    Tabor, Ann
    Jorgensen, Niels
    Andersen, Anders Nyboe
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2017, 217 : 44 - 52
  • [22] Anti-Mullerian hormone concentrations in women with chronic kidney disease
    Wiles, Kate
    Anckaert, Ellen
    Holden, Francesca
    Grace, Jan
    Nelson-Piercy, Catherine
    Lightstone, Liz
    Chappell, Lucy C.
    Bramham, Kate
    CLINICAL KIDNEY JOURNAL, 2021, 14 (02) : 537 - 542
  • [23] The Clinical Value and Interpretation of Anti-Mullerian Hormone in Women With Cancer
    Anderson, Richard A.
    Su, H. Irene
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [24] In Young Infertile Women Low Serum Anti-Mullerian Hormone is Not a Good Predictor of Ongoing Clinical Pregnancy Rate
    Park, Selena
    Brasile, Deanna Rose
    Dampier, William
    Berkowitz, Karen
    OBSTETRICS AND GYNECOLOGY, 2019, 133 : 19S - 20S
  • [25] Anti-Mullerian Hormone as Predictor of Future and Ongoing Bone Loss During the Menopause Transition
    Karlamangla, Arun S.
    Shieh, Albert
    Greendale, Gail A.
    Yu, Elaine W.
    Burnett-Bowie, Sherri-Ann M.
    Sluss, Patrick M.
    Martin, Deborah
    Morrison, Anthony
    Finkelstein, Joel S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 (07) : 1224 - 1232
  • [26] Pregnancy prognosis in women with anti-Mullerian hormone below the tenth percentile
    Koshy, Aby Kottal
    Gudi, Anil
    Shah, Amit
    Bhide, Priya
    Timms, Peter
    Homburg, Roy
    GYNECOLOGICAL ENDOCRINOLOGY, 2013, 29 (07) : 662 - 665
  • [27] Impact of breast cancer on anti-mullerian hormone levels in young women
    Su, H. I.
    Flatt, S. W.
    Natarajan, L.
    DeMichele, A.
    Steiner, A. Z.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 137 (02) : 571 - 577
  • [28] Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women
    Kevenaar, Marlies E.
    Themmen, Axel P. N.
    Laven, Joop S. E.
    Sonntag, Barbara
    Fong, Sharon Lie
    Uitterlinden, Andre G.
    de Jong, Frank H.
    Pols, Huibert A. P.
    Simoni, Manuela
    Visser, Jenny A.
    HUMAN REPRODUCTION, 2007, 22 (06) : 1547 - 1554
  • [29] Does estrogen directly modulate anti-mullerian hormone secretion in women?
    Liberty, Gad
    Ben-Chetrit, Avraham
    Margalioth, Ehud J.
    Hyman, Jordana H.
    Galoyan, Narine
    Eldar-Geva, Talia
    FERTILITY AND STERILITY, 2010, 94 (06) : 2253 - 2256
  • [30] Anti-Mullerian hormone levels and risk of type 2 diabetes in women
    Verdiesen, Renee M. G.
    Onland-Moret, N. Charlotte
    van Gils, Carla H.
    Stellato, Rebecca K.
    Spijkerman, Annemieke M. W.
    Picavet, H. Susan J.
    Broekmans, Frank J. M.
    Verschuren, W. M. Monique
    van der Schouw, Yvonne T.
    DIABETOLOGIA, 2021, 64 (02) : 375 - 384